Trial of Rezum Water Vapor Therapy for benign prostatic hyperplasia is published in Urology.- Boston Scientific
Boston Scientific Corporation announced that data from a randomized clinical trial demonstrate that Rezum Water Vapor Therapy, a minimally invasive treatment for benign prostatic hyperplasia (BPH), provides durable results and preserves sexual function four years after treatment. The study, published online ahead of print by Urology, found that patients continued to experience significant and sustained improvement in their symptoms and quality of life over this period.
In particular, lower urinary tract symptoms were significantly improved within 3 months after thermal therapy and remained consistently durable (IPSS 46%, QOL 42%, Qmax 50%, BPH Impact Index 51%) throughout 4 years; outcomes were similarly sustained in crossover subjects at 3 years. Surgical retreatment rate was 4.4% over 4 years. No disturbances in sexual dysfunction were reported.
See: "Rezum Water Vapor Thermal Therapy For Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: 4-Year Results From Randomized Controlled Study" Kevin T. McVary et al. Urology Published online: January 21, 2019 DOI: https://doi.org/10.1016/j.urology.2018.12.041
Related news and insights
Medtronic announced the United States launch of the Penditure left atrial appendage (LAA) exclusion system, an implantable clip preloaded on a single-use delivery system for LAA management during concomitant cardiac surgery procedures
GSK plc announced positive headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma